Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer.

Abstract

BACKGROUND:

The aim of this study was to investigate the clinical significance of the effect of age on disease control in men who received high-dose intensity-modulated radiation therapy (IMRT) for nonmetastatic prostate cancer (NMPCa).

METHODS:

NMPCa patients with favorable intermediate to very high-risk features (National Comprehensive Cancer Network risk classification) treated with IMRT at our institution between September 2000 and May 2011 were analyzed retrospectively. Treatment consisted of high-dose IMRT (74-78 Gy/37-39 fractions) combined with 6 months of neoadjuvant hormonal therapy. Multivariable analysis using Fine and Gray's regression model was performed to evaluate whether age at initiation of IMRT was associated with biochemical failure (BF) and castration-resistant prostate cancer (CRPC) progression.

RESULTS:

A total of 367 patients were analyzed. The median follow-up period was 8.8 years after IMRT. The 5- and 10-year BF rates were 22.1 and 31.7%, and those of CRPC rates were 4.5 and 12.6%, respectively. Multivariable analysis revealed that a younger age (cut-off: 70 years old) at the initiation of IMRT was significantly correlated with both a higher BF rate (hazard ratio: 1.691, P= 0.0064) and higher CRPC rate (hazard ratio: 2.579, P = 0.0079).

CONCLUSIONS:

Younger men with NMPCa had increased risks of BF and CRPC after high-dose IMRT, and may benefit from more intensive treatments. Our findings should be further tested in prospective studies.

• Authors: Rihito Aizawa, Kenji Takayama, Kiyonao Nakamura, Takahiro Inoue, Toshinari Yamasaki, Takashi Kobayashi, Shusuke Akamatsu, Osamu Ogawa, Takashi Mizowaki
• Journal: Urologic oncology (Urol Oncol) Vol. 39 Issue 2 Pg. 131.e9-131.e15 (02 2021) ISSN: 1873-2496 [Electronic] United States
• PMID: 33127301 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Prostate-Specific Antigen

Topics

• Age Factors
• Aged
• Disease Progression
• Humans
• Male
• Neoplasm Recurrence, Local (blood, epidemiology)
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (blood, radiotherapy)
• Prostatic Neoplasms, Castration-Resistant (epidemiology)
• Radiotherapy, Intensity-Modulated
• Retrospective Studies
• Risk Assessment